who should not take glp-1 drugs glp 1 Medications Infographic Use of GLP-1 drugs early

Although this was demonstrated in animal experiments, GLP-1 was shown to exert acute anti-inflammatory and antioxidant effects on humans under specific conditions

Examples of insurance plans that cover weight loss medication We found several insurance plans that cover weight loss and obesity medications: The Blue Cross Blue Shield Federal Employee Program covers name-brand Wegovy, Saxenda, Contrave, Xenical, Qsymia, and Lomaira, and generic benzphetamine, diethylpropion, orlistat, phendimetrazine, and phentermine

Many communities offer medication take-back programs, and the FDA provides guidance on safe home disposal when take-back options are unavailable

As previously mentioned, patients with T2D on incretin-based therapies showed significant weight loss and improved glycemic control with little experience of hypoglycemia (47)

Similar neuroprotective effects have been reported in various PD rodent models treated with GLP-1R agonists [[844], [845], [846], [847], [848], [849]]

This means we have a lot of evidence about both their effectiveness as well as their long-term risks.1 To finally arrive at a brisk answer to the above question: Yes, GLP-1 drugs seem like the real deal, even if the specifics of their broad benefits remain uncertain